Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid against subcutaneous multiple myeloma tumors in immunodeficient mice.
Bruce Galton, president and CEO of Senesco, said: “VGXI’s manufacturing and technical expertise in producing plasmids for Senesco’s planned toxicology study and ultimately our clinical trial led us to choose them.”